Health committee  If I could add as well, and I apologize for jumping in on Dr. Halperin's question, but the fact is that this is where collaboration occurs. To produce 60 million doses of infant vaccines each year on the Toronto site, this is where we have to sit down and talk. We could potential

Health committee  Just remember there are actually companies like GlaxoSmithKline. GlaxoSmithKline has a great pandemic plan. The only problem is it's for influenza. We didn't expect it for COVID. There needs to be some expansion on the infectious diseases that we're covering in pandemic plans.

Health committee  My expertise is in vaccines. It is extremely difficult to make biologic products. If you're developing an infant vaccine, for example, Pediacel, if you have a quality issue, that whole vat will have to be removed, and that is an 18-month delay. We have to replenish the supply.

Health committee  The epidemiology has been fairly clear on this in regard to who are the most vulnerable. Certainly, they are people who are the most frail in our community, and it's quite horrible when you look at Canada and the statistics for Canada. Initially, when you were looking at the mort

Health committee  Thank you very much for the question. “Promising” is an interesting word. It's almost like what is coming first. We have a number of vaccines that are coming first. There's one in particular out of Oxford that is associated with AstraZeneca. It is a vector form of vaccine with a

Health committee  I don't think there's going to be a single vaccine that's going to be the solution. A lot of that has to do with production capacity. We will have, hopefully, many successful safe and efficacious vaccines, and then we will see the manufacturing and production ability. I underst

Health committee  —do our best. I've been in great communication with Health Canada. It has asked me to find small biotechs in Canada that we can introduce to Health Canada, to find the best research possibilities. It's not a guessing game here. This is a science game. We have to find the best op

Health committee  There are about 150 different companies across the world that have SARS-CoV-2 candidate vaccines. These are distributed into different types. It seems mRNA vaccines and subunit vaccines are the ones people are working on. It is extremely complicated to make a vaccine, because it

Health committee  With regard to the research funds, my company Sanofi has not benefited, but other companies have. This is not about one or two different companies. Across the board we have to try to—

Health committee  Many of the IMC companies are, in fact, global companies. We will be working to develop vaccines, and when we develop those vaccines, it will be based on many of the volumes that we will...to understand the distribution. I think one of the most important things is that it may ne

Health committee  Yes. Thank you. Part of what's going to be happening is the distribution of the vaccines. We have global organizations, in which Canada is involved, to understand how we will be distributing those vaccines. That also depends on, specifically, which company would produce the vacc

Health committee  Yes, I would say that, and I would actually direct you to Dr. Halperin at this point.

Health committee  Mr. Chair, for over 100 years, through innovation, altruism and collaboration, Canada has successfully responded to infectious disease outbreaks. From Dr. John FitzGerald and the University of Toronto preparing a diphtheria and tetanus antitoxin to vaccine researchers developing